Hepatoprotective effects of whey protein on D-galactosamine-induced hepatitis and liver fibrosis in rats.
The hepatoprotective effects of whey protein on two injections of D-galactosamine (300 mg/kg, i.p.) were investigated in rats fed a modified AIN-93M diet formulated with a protein source of casein or whey for 16 d. The whey protein-containing diet clearly suppressed an increase in plasma alanine and aspartate aminotransferase activity, lactate dehydrogenase and bilirubin, which are hepatitis markers, and also hyaluronic acid, a fibrosis marker. In addition, it suppressed histopathological signs of portal fibrosis, bile duct proliferation, and perivenular sclerosis. These results suggest that supplementation with whey protein can help prevent the development of hepatitis and portal fibrosis.
Kume
Hisae
H
Department of Nutritional Research, Food Science Institute, Meiji Dairies Corporation, Odawara, Japan. HISAE_KUME@MEIJI-MILK.COM
Okazaki
Keiko
K
Sasaki
Hajime
H
D000409:Alanine / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology / Q000517:prevention & control*; D004032:Diet; D005526:Food, Formulated; D005688:Galactosamine / Q000633:toxicity; D006820:Hyaluronic Acid / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008103:Liver Cirrhosis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008894:Milk Proteins / Q000008:administration & dosage*; D020011:Protective Agents / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000067816:Whey Proteins
D008894:Milk Proteins; D020011:Protective Agents; D000067816:Whey Proteins; D005688:Galactosamine; D006820:Hyaluronic Acid; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000409:Alanine; D001663:Bilirubin